An Updated Systematic Review and Meta-Analysis of Mortality, Need for ICU admission, Use of Mechanical Ventilation, Adverse effects and other Clinical Outcomes of Ivermectin Treatment in COVID-19 Patients

*Smruti Karale, MBBS[1]; *Vikas Bansal, MBBS, MPH[2]; Janaki Makadia, MBBS[3]; Muhammad Tayyeb, MD[4]; Hira Khan, MBBS[5]; Shree Spandana Ghanta, MBBS[6]; Romil Singh, MBBS[7]; Aysun Tekin, MD[8]; Abhishek Bhurwal, M9[8]; Hemant Mutneja, MD[10]; Ishita Mehra, MBB[11]; Rahul Kashyap, MBBS, MBA[8]

[1]Medical Graduate, Government Medical College Kolhapur, Kolhapur, India

[2]Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, MN, USA

[3]Medical Graduate, GMERS Medical College, Vadodara, Gujarat, India

[4]Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ, USA

[5]Department of Neurology, Allegheny General Hospital, Pittsburgh, PA, USA

[6]Department of Internal Medicine, St. Elizabeth's Medical Center, Boston, MA, USA

[7]Department of Internal Medicine, Allegheny General Hospital, Pittsburgh, PA

[8]Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Rochester, MN, USA

[9]Department of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School of Medicine, New Brunswick, NJ, USA

[10]Division of Gastroenterology, Cook County Hospital, Chicago, Illinois

[11]Department of Internal Medicine, North Alabama Medical Center, Florence, AL, USA

Corresponding Author:

Vikas Bansal, MBBS, MPH

Assistant Professor of Medicine

Division of Pulmonary and Critical Care Medicine

Mayo Clinic, Rochester, MN- 55905

Email: bansal.vikas@mayo.edu

Phone: +1-507-398-1595

Word count: Abstract: 250; Manuscript: 5041

Tables: 0 main, 8 supplemental

Figures: 6 main, 31 supplemental

Conflicts of Interest: None of the authors have reported any conflicts of interest.

Financial Support: There is no financial disclosure related to this study.

Author Contribution: *Authors 1(SK) and 2(VB) contributed equally in defining the study

outline and manuscript writing. Data review and collection were done by HK, JM, SG, RS, SK,

and MT; statistical analysis done by SK, VB, and AB. Quality assessment of studies was done by

AT,JM, HK, MT, SK, VB and GRADE quality rating was done by AB, HM and VB. Study

design, distribution of articles for critical review done by SK, VB and RK. Final approval was

received from all authors. SK and VB is the guarantor of the paper, taking responsibility for the

integrity of the work as a whole, from inception to published article.

Acknowledgment: We acknowledge Dr. Anant Mohan, Dr. Asma Asghar, Dr. Flavio Cadegiani,

Dr. Houssam Raad, Dr. José Morgenstern, Dr. Morteza Niaee, Dr. Nasir Afsar, Dr. Nurullah

Okumus, Dr. Olufemi Babalola, Dr. Pablo Méndez-Hernández, Dr. Ravi Kirti, Dr.Ravindra

Ghooi, Dr. Reaz Mahmud and Dr. Tasnim Ahsan for their correspondence and contribution.

Keywords: Ivermectin, COVID-19, SARS-CoV-2, Mortality, ICU, Mechanical ventilation,

adverse effect, Systematic Review, Meta-analysis

Short tile: Clinical Outcomes Associated with Ivermectin use in COVID-19: An Updated

Systematic Review And Meta-Analysis

Highlights

What We Already Know about This Topic

1.   COVID-19 is an ongoing global pandemic, for which Ivermectin has been tried on a

therapeutic and prophylactic basis.

2.   Results from several clinical trials and observational studies suggest that Ivermectin may

improve survival and clinical outcomes with a good safety profile when compared with

other treatments; however, the current evidence is limited. .

What This Article Tells Us That Is New

1.   This systematic review and meta-analysis provide a summary of the latest literature on

the efficacy and safety of Ivermectin use for COVID-19.

2.   Based on our analysis of the latest evidence, we found that Ivermectin's benefit in

reducing mortality cannot be concluded with confidence . However, as an adjuvant

therapy it may help reduce the need for hospitalization, duration for viral clearance while

increasing the likelihood of achieving viral clearance.

3.   We need more high-quality data for conclusive evidence regarding the benefit of

Ivermectin in reducing the need for ICU admissions ,mechanical ventilation and duration

of hospital stay in COVID-19 patients.

List of abbreviations

ARDS: Acute respiratory distress syndrome

CDC: Centers for Disease Control and Prevention

COVID-19: Coronavirus Disease 2019

DNA: Deoxyribonucleic Acid

EMA: European Medicines Agency

FDA: Food and Drug Administration

ICU: Intensive Care Unit

IRB: Institutional Review Board

NIH: National Institutes of Health

RCT: Randomized controlled trial

RNA: Ribonucleic Acid

RT-PCR: Reverse Transcription Polymerase Chain Reaction

IMP: Importin

SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2

WHO: World Health Organization

Abstract

Importance: Repurposing Ivermectin, a known anti-parasitic agent, for treating COVID-19 has

demonstrated positive results in several studies. We aim to evaluate the benefit and risk of

Ivermectin in COVID-19.

Methods: We conducted a systematic search for full-text manuscripts published from February

1, 2020, to August 15th, 2021 focusing on Ivermectin therapy against COVID-19. The primary

outcomes were mortality, need for intensive care unit (ICU) admission; secondary outcomes

were - adverse effects, need for mechanical ventilation, viral clearance, time to viral clearance,

need for hospitalization, and length of hospital stay. Random-effects models were used for all

analyses.

Results: We included a total of 52 studies (n=17561) in the qualitative analysis, out of these, 44

studies (n=14019) were included in the meta-analysis. In the mortality meta-analysis (N=29),

odds of death were lower in the Ivermectin-arm compared to control (OR 0.54, p=0.009).

Although lower odds of mortality were observed in various subgroup analyses of RCTs, they did

not reach statistical significance: therapeutic RCTs: mild-moderate COVID-19 (OR 0.31,

p=0.06), therapeutic RCTs: severe/critical COVID-19 (OR 0.86, p=0.56), inpatient RCTs: mild-

moderate COVID-19 (OR 0.18, p=0.08), inpatient RCTs: severe/critical COVID-19 (OR 0.86,

p=0.56). Ivermectin, mostly as adjuvant therapy, was associated with higher odds of viral

clearance (N=22) (OR 3.52, p=0.0002), shorter duration to achieve viral clearance (N=8) (MD -

4.12, p=0.02), reduced need for hospitalization (N=6) (OR 0.34, p=008).

Conclusion: Our meta-analysis suggests that the mortality benefit of Ivermectin in COVID-19 is

uncertain. But as adjuvant therapy, Ivermectin may improve viral clearance and reduce the need

for hospitalization.

Introduction

On March 11, 2020, the World Health Organization (WHO) declared COVID-19 disease

a global pandemic[1]. Today, on September 9,2021, there are about >222 million confirmed cases

worldwide and >4.6 million deaths due to COVID-19[2]. Patients infected with SARS-COV-2, the

causative Coronavirus, exhibit a spectrum of clinical presentations ranging from asymptomatic to

severely critical and multiple risk factors are involved in the prognosis of the disease[3-8]. To guide

decision-making for this multi-system disease[8-17], a variety of treatment modalities have been

proposed and evaluated[18-23]. However, the evidence for the risk-benefit ratio of most of these

treatments remains unclear.

Ivermectin has held an excellent safety record in humans as an antiparasitic agent for

over three decades[24]. Apart from its established activity against several parasites, Ivermectin has

demonstrated antiviral activity against many RNA and DNA viruses in vivo and against a few in

vitro by targeting specific proteins[25]. One such plausible mechanism against RNA viruses is the

inhibition of importin (IMP) α/β Integrase , thus blocking viral entry into the nucleus and the

ensuing suppression of the cell's anti-viral response[25-28]. Moreover, it exhibited anti-bacterial,

anti-inflammatory, and anti-cancer effects[24,29,30]. An Australian study demonstrated the

effectiveness of Ivermectin in inhibiting SARS-COV2 in-vitro[31]. Subsequently, several

Ivermectin-based clinical trials and observational studies conducted globally showed mostly

positive results[32-35]. Some countries have incorporated this therapy in their COVID-19

guidelines[36-39]. Only a month after this authorization, Peru witnessed a record drop of 25% in

COVID-19 related mortality[40].

Dr. Satoshi Ōmura, who was among the scientists that won the Nobel prize for the

discovery of Ivermectin, highlighted the need to develop a drug that arrests the early stage of

viral replication in COVID-19[41]. Repurposing Ivermectin, a low-cost drug may help bypass the

time and funds needed to develop and test novel therapies. The lack of robust evidence has been

a major hindrance in the large-scale approval of Ivermectin. The available studies are

methodologically diverse and mostly under-powered while few report conflicting results.

Therefore, we intend to systematically review the latest literature and plan to perform a meta-

analysis to overcome some of the individual study biases.

Methods:

Search Method and strategy

We conducted a comprehensive literature search for studies mentioning the use of

Ivermectin in COVID-19 from February 1, 2020 till August 15, 2021 (Figure 1). We screened all

titles and abstracts identified by preliminary search for eligible studies and manually searched

references of included articles for additional studies. Then we analyzed full-text manuscripts of

included studies according to the protocol of Systematic Review and Meta-Analysis (PRISMA)

guidelines.

Eligibility Criteria

We included studies reporting outcomes of mortality, ICU admission, mechanical

ventilation, adverse-effects, viral clearance, hospitalization with therapeutic Ivermectin treatment

against COVID-19. We excluded studies focusing on pregnant females, in- vitro studies, meta-

analyses, case reports and case series <5 patients.

Study selection and data extraction

The extracted data was tabularized in Microsoft Excel with following parameters: author,

country of study, study design, number of patients, Ivermectin regimen, concomitant treatment,

efficacy outcomes and adverse effects. The included data was checked for accuracy by all

authors and disagreements were resolved through consensus and after input from a third

reviewer. IRB approval was exempted because data was extracted from publicly available

studies. We also analyzed raw data files or supplemental files of studies by Cadegiani[42] and

Lima-Morales et al[43] for outcomes of cases receiving Ivermectin, Niaee et al[44] for clinical

severity based mortality data and duration of hospital stay, Choudhary et al[35] for time for viral

clearance, Mahmud et al[45] for need for hospitalization, Ghooi et al[46] for mortality in Ivermectin

receiving patients, Samaha et al[47] for viral clearance. In Cadegiani et al's study[42], we considered

'CG1' as control group because only this sample was demographically comparable to the

treatment group. Additionally, we compiled all ongoing clinical trials on Ivermectin from

clinicaltrials.gov (e-Table-8). We excluded the study by Elgazzar et al[48] because it was retracted.

Outcomes

The primary outcome was defined as mortality benefit with Ivermectin therapy in

COVID-19 and need for ICU admission. The secondary outcomes were need for mechanical

ventilation ,adverse effects of Ivermectin, viral clearance and time to achieve viral clearance,

need for hospitalization and duration of hospital stay.

Statistical analysis

Primary and Secondary outcomes were quantitatively analyzed by Review Manager

(RevMan) Version 5.4 for windows[49] and Comprehensive Meta-Analysis software package

(Biostat, Englewood, NJ, USA)[50] was used for pooled-analysis. Random-effects model was used

for both[51]. Raw data for outcomes and non-events from each study were used to calculate crude

odds ratio (OR) with 95% confidence intervals (CI) for each study. The Cochrane Q and I^2

statistics were calculated to assess heterogeneity between studies[51]. $I^2 < 25\%$ were interpreted as

low-level heterogeneity[51]. We performed subgroup analysis by study design to decrease inherent

selection bias in observational studies[51]. Probability of publication bias was assessed with funnel

plot using Egger's tests[51] (e-Figure 15-31). If there was statistical heterogeneity in results, further

sensitivity analysis was conducted to determine the source of heterogeneity by excluding each

study. After significant heterogeneity was excluded, random-effects model was used for meta-

analysis. For sensitivity analysis, if we found heterogeneity to be similar with different studies'

exclusion, we chose to present the result with lowest odd's ratio. P-value <0.05 (2-sided) was

considered statistically significant[51].

Risk of Bias and Quality assessment

Clinical trials were evaluated using Cochrane risk of bias tool[52] (e-Table 2) and

correlation of quality measures with estimates of treatment effects in meta-analyses of

randomized controlled trials tool[53] (e-Table 3) was used for quality assessment. We used NIH

quality assessment Tool for case series[54] (e-Table 4), case-control (e-Table 5), or cohort studies

(e-Table 6). NIH quality assessment tools were based on quality assessment methods, concepts,

and other tools developed by researchers in the Agency for Healthcare Research and Quality

(AHRQ), Cochrane Collaboration, USPSTF, Scottish Intercollegiate Guidelines Network, and

National Health Service Centre for Reviews and Dissemination, consulting epidemiologists and

evidence-based medicine experts, with adaptations by methodologists and NHLBI staff. We

assessed the certainty of evidence by using GRADE pro profiler[55] (GRADE working group,

McMaster University and Evidence Prime Inc) at the outcome level (e-Table 7).

Results

Study Characteristics

A total of 17561 patients from 52 articles[32-35,42-47,56-97] (Ivermectin n=7509, No

Ivermectin n= 10052) were included in the pooled analysis , 14019 patients from 44 studies

(Ivermectin n=3913, No Ivermectin n=10106) were included in quantitative synthesis (e-Table 1,

Figure 1). Out of 33 trials, 26 were true RCTs (e-Table 1, Figure 1). The remaining 19 studies

were observational and included 6 case-series (e-Table 1, Figure 1). Out of 52, 13 articles were

available as preprints, Huvemec trial[76] details were obtained online and clinicaltrials.gov was

used for data extraction for 1 trial[65] (e-Table 1, Figure 1). Due to absence of informed consent,

blinding and randomization, we considered Veerapaneni et al's[93] study as case control study.

Primary Outcomes

(A) Mortality

Meta-analysis Overall

Total 29 studies reported mortality rate in patients receiving Ivermectin (279/3240) vs no-

Ivermectin therapy (1347/9407). The odds of mortality in the Ivermectin group were lower

compared to control group but the heterogeneity was high (OR 0.54, 95% CI 0.34-0.86, p=0.009;

I^2=75%) (Figure 2A). Evidence was graded very low (e-table 7). In sensitivity analysis, we

observed similar mortality benefit with moderate heterogeneity after excluding study by Soto-

Becerra et al[92] (OR 0.49, 95% CI 0.32-0.75, p=0.001; I^2=52%) (Figure 2B).

Subgroup analysis by study design

Subgroup: Clinical trials

We performed subgroup analysis of 18 clinical trials (RCTs N=15, Non-RCTs N=3) and

observed similar mortality benefit (OR 0.47, 95% CI 0.25-0.90, p=0.02; I^2=59%) (Figure 3A) but

evidence was graded low (e-table 7). On excluding Lima-Morales et al[43] for sensitivity analysis,

benefit was observed with low heterogeneity but was not statistically significant (OR 0.61, 95%

CI 0.37-1.02, p=0.06; I^2=19%) (e-Figure 1).

Subgroup: RCTs

We analyzed clinical severity-based data in 15 RCTs which included patients treated with

Ivermectin on inpatient or outpatient basis. In the mild/moderate subgroup, the odds of mortality

were lower with moderate heterogeneity but did not reach statistical significance (OR 0.31, 95%

CI 0.09-1.04, p=0.06; I^2=45%) (Figure 3B). Similarly, mortality benefit was not statistically

significant in the severe/critical subgroup (OR 0.86, 95% CI 0.51-1.45, p=0. 56; I^2=0%) (Figure

3C). Certainty of evidence was low in the mild/moderate and severe/critical subgroup (e-table 7).

In sensitivity analysis, after excluding Vallejos et al[96] from the mild-moderate subgroup,

the odds of mortality decreased with low heterogeneity and reached statistical significance (OR

0.21, 95% CI 0.06-0.69, p=0.01; I^2=24%) (e-Figure 2). Therefore, in mild/moderate COVID-19

patients, Ivermectin may possibly be useful for reducing mortality when we used as an adjuvant

therapy.

Observational studies

230   Mortality benefit was not statistically significant in subgroup analysis of 11 observational

231 studies (OR 0.64, 95% CI 0.35-1.16, p=0.14; I^2=73%) (Figure 3D) and evidence was graded very

232 low (e-table 7). After excluding Soto-Becerra et al[92] in sensitivity analysis, we observed

233 statistically significant mortality benefit with moderate heterogeneity (OR 0.54, 95% CI 0.32-

234 0.92, p=0.02; I^2=38%) (e-Figure 3).

Subgroup analysis for hospitalized patients

Overall

237   In the subgroup analysis for hospitalized patients (studies N=18) mortality benefit was

238 not statistically significant (OR 0.65, 95% CI 0.42-1.00, p=0.05; I^2=66%) (Figure 3E). Evidence

239 was very low (e-table 7). After excluding Soto-Becerra et al[92] in sensitivity analysis, we

240 observed statistically significant lower odds of mortality with moderate heterogeneity (OR 0.58,

241 95% CI 0.39-0.87, p=0.008; I^2=37%) (e-Figure 4).

Subgroup: Inpatient RCTs

We analyzed clinical severity-based data in 9 RCTs with only hospitalized patients. It

showed mortality benefit that was not statistically significant in the mild-moderate COVID-19

subgroup (OR 0.18, 95% CI 0.02-1.25, p=0.08; I^2=61%) (Figure 3F) and in the severe/critical

COVID-19 subgroup (OR 0.86, 95%CI 0.51-1.45, p=0.56; I^2=0%) (Figure 3G). Evidence was

graded low in both the subgroup analyses (e-table 7). After excluding Abd-elsalam et al[94] in

sensitivity analysis for mild-moderate COVID-19, mortality benefit was statistically significant

(OR 0.06, 95% CI 0.01-0.33, p=0.001; I^2= 0%) (e-Figure 5).

Subgroup: Inpatient Observational studies

251 In the analysis of 8 observational studies with only hospitalized patients, significant

252 mortality benefit was not seen, and heterogeneity was high (OR 0.70, 95% CI 0.38-1.30, p=0.26;

253 I^2=77%) (Figure 3H). Evidence was graded very low (e-table 7). In sensitivity analysis, after

254 excluding Soto-Becerra et al[92] no significant mortality benefit was seen and heterogeneity was

255 moderate (OR 0.58, 95% CI 0.32-1.05, p=0.07; I^2=50%) (e-Figure 6).

(B) Effect of Ivermectin monotherapy compared with Placebo/Standard of Care as per Cochrane's criteria

We identified 7 RCTs where they investigated the effect of ivermectin monotherapy with or

without standard of care compared to placebo or standard of care. Overall, no significant

mortality benefit was observed (OR 0.75, 95%CI 0.35-1.63, p=0.47; I^2=0%) (Figure 4). In

severity based subgroup analysis, the result remained same for mild/moderate subgroup (OR

0.71, 95% CI 0.27-1.87, p=0.49; I^2=0%) and severe/critical subgroup (OR 0.83, 95% CI 0.23-

3.02, p=0.78; I^2=NA) (Figure 4). Certainty of evidence was moderate overall and in the

mild/moderate subgroup, however it was graded low in severe/critical subgroup due to small

sample size (e-table 7).

Pooled Analysis for mortality

267 Pooled analysis of 37 studies out of 52 studies, yielded a rate of 3.6%, 95% CI 2.1-6.3;

268 I^2=93.87% (e-Figure 7).

(C) Need for ICU admission

Meta-analysis

In 5 studies (out of 52), 27/263 in the Ivermectin arm, 52/322 in the control arm needed

ICU admission. Benefit with Ivermectin was not statistically significant (OR 0.48, 95% CI 0.17-

1.37, p=0.17; I^2=59%) (Figure 5A). Evidence was graded very low (e-table 7). In sensitivity

analysis, after excluding Galan et al[71] we observed statistically significant benefit (OR 0.32, 95%

CI 0.11-0.92, p=0.03; I^2=27%) (Figure 5B). Based on low grading of evidence and observed

low-moderate heterogeneity in analysis, Ivermectin may be helpful in combination therapy in

decreasing need for ICU admission. Further validation with well-designed pragmatic platform

trials is needed.

Pooled Analysis

280 Pooled ICU admission rate obtained from 8 studies out of 52 studies was 5.4%, 95% CI

281 1.9-14.7; I^2=91.9% (e-Figure 8).

Secondary Outcomes

(A) Need for Mechanical Ventilation

Meta-analysis

Overall, 12 studies documented the need for mechanical ventilation. 71/1362 patients receiving Ivermectin and 88/1154 patients in the control arm required mechanical ventilation. The benefit of Ivermectin was not statistically significant (OR=0.75, 95%CI 0.52-1.08, p=0.12; I^2=0%) (Figure 5C). Evidence was graded very low (e-table 7). On excluding Galan et al[71] in sensitivity analysis, benefit observed was not statistically significant and showed no heterogeneity (OR 0.68, 95% CI 0.45-1.01, p=0.06; I^2=0%) (Figure 5D).

Pooled Analysis

The rate of need for mechanical ventilation based on 14 studies (out of 52 studies) was 3.9%, 95% CI 1.7-8.6; I^2=87.2% (e-Figure 9).

(B) Adverse events

Meta-analysis

A total of 22 studies reported data for rate of adverse-events in the Ivermectin-arm (292/1405) vs control group (288/1372). We did not find an association between Ivermectin and rate of adverse events as compared to controls (OR 0.87, 95% CI 0.67- 1.13, p=0.30; I^2=1%). (Figure 5E) but evidence was graded very low (e-table 7). In sensitivity analysis, after excluding Veerapaneni et al[93] incidence of adverse effects with Ivermectin was similar to that of the control group but was not conclusive (OR 0.84, 95% CI 0.65-1.08, p=0.18; I^2=0%) (Figure 5F).

Pooled Analysis

A total of 38 studies (out of 52 studies) yielded a pooled rate of 6.6%, 95% CI 3.9-11.1; I^2=92.2% (e-Figure 10).

(C) Viral Clearance

Twenty-two studies reported data for patients achieving viral clearance: 1036/1327 in the Ivermectin arm while 790/1206 patients in the non-Ivermectin arm tested negative for RT-PCR. The analysis indicated that patients in the Ivermectin-arm showed higher odds of achieving viral clearance when compared to the control group at a given point in time (OR 3.52,95%CI 1.81-6.86, p<0.01; I^2=85%) (figure 6A). Evidence level was low (e-table 7). When we excluded Mourya et al[85] in the sensitivity analysis, similar benefit was observed but heterogeneity remained high (OR 2.79, 95%CI 1.52-5.10, p<0.01; I^2=81%) (e-figure 11).

(D) Time to achieve Viral Clearance

Eight studies presented data for the time needed for viral clearance in the Ivermectin receiving arm vs that in the non-Ivermectin arm. The results show that the time needed to achieve viral clearance was shorter by over 4 days in the Ivermectin group as compared to the non-Ivermectin group, but with high heterogeneity (MD -4.12,95%CI -7.59,-0.65, p=0.02; I^2=98%) (figure 6B). Evidence level was low (e-table 7). In sensitivity analysis, benefit was seen but heterogeneity remained high after excluding Khan et al's study[77] (MD -3.24, 95%CI -5.37,-1.10, p=0.003; I^2=92%) (e-figure 12).

(D) Need for hospitalization

Six studies described information for the number of patients requiring hospitalization when receiving Ivermectin (113/1074) as compared to those not receiving it (212/947). As per the analysis, Ivermectin group showed lower need for hospitalization as compared to controls but with high heterogeneity (OR 0.34, 95%CI 0.16-0.75, p=0.008; I^2=78%) (Figure 6C). Evidence was low grade (e-table 7). On excluding Lima Morales et al[43] in sensitivity analysis, similar

benefit was seen with moderate heterogeneity but without statistical significance (OR 0.43, 95%

CI 0.18-1.01, p=0.05; I^2=59%) (e-figure 13).

(F) Length of hospital stay

We analyzed data from 9 studies regarding the duration of hospital stay in the Ivermectin

vs control arm. In this meta-analysis, we found that the benefit of Ivermectin in reducing the

duration of hospital stay was not statistically significant and heterogeneity was high (MD -1.80,

95% CI -3.69,0.08, p= 0.06; I^2=94%) (Figure 6D). Evidence was low grade (e-table 7). In the

sensitivity analysis, we excluded Khan et al's study[72] and the duration of hospital stay was

shorter by one day in the Ivermectin arm compared to non-Ivermectin arm with high

heterogeneity and no statistical significance (MD -1.16, 95%CI -2.42,-0.1, p=0.07; I^2=84%) (e-

figure 14).

Discussion

Our meta-analysis suggests that the role of Ivermectin in improving patient survival in

COVID-19 is uncertain. However, Ivermectin might help more patients achieve viral clearance,

in a shorter duration of time and may also help reduce the need for hospitalization when used in

combination therapy. Its benefit in reducing the need for admission to the ICU, mechanical

ventilation and the duration of hospital stay cannot be concluded with confidence. Its relation to

the incidence of adverse effects is inconclusive. Further, our pooled analysis indicates that

Ivermectin treatment may be linked to lower death rate and better clinical outcomes with a low

incidence of adverse effects**.** The inherent methodological limitations and risk of bias conferred

variable evidence grading in the findings in various patient outcomes.

Mortality

Several systematic review and meta-analysis were performed to investigate the efficacy

of ivermectin for the treatment and prevention of COVID-19, with mixed results in meta-

analyses and conclusions. Meta-analyses done by Padhy et al [98] (studies N=3), Hill et al[99]

(studies N=6) (**retracted**[100]), Lawrie et al[101] (studies N=5), Nardelli et al[102] (studies N=7), Kow

et al[103] (studies N=6), Bryant et al[104] (studies N=13), Kory et al[105] (studies N=10), Hariyanto et

al[106] (studies N=8) and the BIRD group[107] (studies N=13) found Ivermectin to be conclusively

linked to lower mortality when compared to usual treatment. A network meta-analysis[108] (studies

N=2) reported that Ivermectin was linked to lower mortality with a very close statistical

significance. Casteneda-Sabogal et al's meta-analysis[109] (studies N=6) and Roman et al[110]

(studies N=5) found no conclusive association of Ivermectin with reduced mortality. Of note, the

above three studies[108-110] reported low or very low certainty of evidence. However, most of the

above analyses have included the retracted study by Elgazzar et al[48]. Recently published

Cochrane's review[111] of highly selected low-risk bias studies aimed at evaluating the true-effect

of Ivermectin in COVID-19. They expressed uncertainty regarding the effect of Ivermectin on

COVID-19 mortality based on 2 outpatient and 2 inpatient RCTs[111]. Our sample size exceeds

(studies N=29) that of all the aforementioned studies. We observed mortality overall (N=29) and

in the clinical trials subgroup (N=18) meta-analysis. However, no mortality benefit was observed

in therapeutic RCTs (mild-moderate N=12, severe/critical N=6), inpatient RCTs (mild-moderate

N=5, severe/critical N=6) and observational studies (overall N=11, Inpatient N=8). Using the

selection criteria used in Cochrane's meta-analysis, we did not observe a mortality benefit when

we limit the analysis for Ivermectin monotherapy in comparison to standard of care or

placebo[111]. We would like to emphasize the fact that the observed mortality benefit in some

analyses was frequently seen when Ivermectin was used in combination therapy especially with

vitamins, trace elements, other antimicrobials, and steroids. Beneficial effect of steroids has been

already been established, which was frequently used as part of standard of care[112]. As we know

proper nutrition and activation of the immune system are two crucial elements in fighting the

COVID-19 infection[113] therefore it is possible that supplemental vitamins and minerals may help

in COVID-19 infection. However, clinical evidence does not currently support routine use of any

of these agents for the prevention or treatment of COVID-19, unless a patient has a confirmed or

suspected micronutrient deficiency[114]. We speculate that the observed mortality benefit of

Ivermectin was influenced by the use of these supplements, either through prescription or

patient's own decision for over the counter use.

Our pooled analysis resulting in a low mortality rate of 3.6% with use of Ivermectin,

mostly as an adjuvant therapy, is suggestive of its positive impact in lowering mortality in

COVID-19 patients. For a valid comparison, it is important to factor in the time window during

which the individual studies were conducted. Most studies recorded their data in the II&III

quarter of 2020 when mortality rates with various treatments were often higher in respective

countries[115]. For instance, the mortality benefit with Ivermectin has been observed on a

magnified basis in a population study of 25 Peruvian states. The analysis of this mass

administration data revealed a 14 fold drop in deaths a couple months after starting of large-

scale Ivermectin use and a 13 fold increase since limiting its use following change in Peru's

political scenario[116].

Need for ICU admission and Mechanical Ventilation

Due to the small number of studies and their small individual sample size, benefit with

Ivermectin in reducing ICU admissions or mechanical ventilation cannot be concluded with

confidence. In our pooled analysis, we observed significantly lower rates for ICU admission

(5.4%) and mechanical ventilation (3.9%) in Ivermectin-treated patients, mostly as an adjuvant

therapy, when compared to other treatments[117-119]. It must be noted that our pooled analysis

mostly included mild/moderate patients, which may skew the results in favor of Ivermectin.

Adverse events

Our analysis for adverse events was inconclusive. We noticed that most adverse events

were non-serious: nausea, vomiting, abdominal pain, diarrhea, pruritus, lethargy, vertigo,

tingling, numbness, anxiety, mild hyperglycemia etc. Yet, very few patients reported serious

events like organizing pneumonia, hyponatremia, erosive esophagitis, infections/infestations.

Erosive esophagitis can be attributed to concomitant use of Doxycycline[120]; hyponatremia[80] was

likely from SIADH-a rare COVID-19 complication[121]. Only Lopez-Medina et al[81] (Ivermectin

dose = 1500ug/Kg over 5 days) and Mahmud et al[45,122] (Ivermectin dose =12mg twice daily for 5

days) reported drug discontinuation due to adverse-reactions. Given the non-serious nature of

most adverse-reactions, and a low pooled rate of 6.6% in comparison to other available

treatments[23,123,124], we suggest that Ivermectin was generally well tolerated.

Viral Clearance and time to achieve Viral Clearance

We observed that patients who received Ivermectin in combination with other drugs were

far more likely to test negative for RT-PCR as compared to the control group. Hariyanto et al's

meta-analysis[106] (N=9) supports our findings. Contrary to our results, Roman et al[110] (N=4) and

Cochrane's review[111] found no such difference.

Similarly, when used in combination therapy, Ivermectin appeared to have significantly

shortened the time to achieve viral clearance when compared to the non-Ivermectin arm. This

finding was also observed in the analysis of Lawrie et al[101] (N=2), Hariyanto et al[106] (N=6) and

the BIRD group[107] (N=4), however, Lawrie et al's[101] results were not statistically significant. It

must be noted that these outcomes are subject to technical variations because of the different

laboratory parameters as well as the day at which viral clearance was measured.

Need for hospitalization and duration of hospital stay

Our analysis suggests that Ivermectin treatment may help reduce the need for

hospitalization. Another study by the BIRD group[107] (N=2) also found this association, yet their

analysis did not reach statistical significance.

In our analysis, we found trends of shorter duration of hospital stay but our results were

not conclusive, hence more data is needed to confirm this finding. Three other studies[101,106,107]

also found similar benefit, only one[107] was not statistically significant. While Roman et al[110]

observed that Ivermectin was associated with a longer hospital stay; but without statistical

significance. Recently, Cochrane's review[111] also did not find an association between Ivermectin

and duration of hospitalization. We must acknowledge the high variation in clinical decision

making as well as the availability of resources with respect to hospitalization outcomes.

Our analysis for the true effect of Ivermectin is inconclusive, which supports the

conclusion of Cochrane's review[111] that Ivermectin may or may not be effective by itself.

COVID-19, being a complex, multi-stage, and multi-system disease, requires a multi-pronged

approach. Hazan et al[97] enumerated several microbial diseases currently being successfully

treated by a combination of multiple drugs with different individual mechanisms of actions. They

highlighted another benefit of multidrug therapy: to avert cases of drug-resistance such as those

occurring with Ivermectin-monotherapy against parasitic infections. This is crucial since the

newly emerging SARS-CoV2 strains have perpetuated the pandemic in spite of desperate

measures taken world-wide. Also, this approach may address concerns regarding the adverse

effects associated with high dose of Ivermectin. Because, drug combinations can possibly boost

drug potency such as with the combination used by Hazan et al[97], thus rendering moderate doses

to be more effective. Therefore, it is imperative that we thoroughly explore Ivermectin as a part

of a multidrug regimen.

On the starting point of the COVID-19 disease spectrum is the acute infectious phase that

lasts for up to 2 weeks and is characterized by viral replication[125]. This is followed by the hyper-

inflammatory state marked by rise in inflammatory markers[125]. Those surviving this phase may

experience long-term multi-organ sequelae for up to six months or even a year[126,127]. Patients

progressing to the severe stage require hospitalization and mortality rates among hospitalized

COVID-19 patients can be as high as 25%[128]. Dwindling economies, overburdened healthcare

systems and the consequent dearth of resources further worsen the prognosis of hospitalized

patients, especially in low-income countries. Once progressed to the critical stage, mortality rate

of around 50% has been recorded[129]. The management of severe and critical patients mainly

consists of supportive treatment for complications of severe COVID-19[130]. The available

evidence of the efficacy and safety of the recommended drugs for severe and critical COVID-19

patients is not promising[131-134]. Even before the pandemic, much emphasis has been laid on the

importance of preventive and early treatment strategies for ARDS and sepsis to achieve a higher

survival rate in patients[135-138]. Drawing upon these recommendations, we hypothesize that

employing Ivermectin as an adjuvant therapy for early treatment of COVID-19 cases may allow

the body to mount an adequate and well-regulated immune response, thus leading to better

outcomes. Considering the bleak prognosis of COVID-19 at the advanced stage, we postulate

that we may potentially improve patient outcomes by actively arresting its progression to severe

stages with effective and safe early adjuvant treatments like Ivermectin. Finally, we suggest that

understanding the course of this disease- both pathophysiological and symptomatic, and

leveraging it is key to achieving the best outcomes at both-patient and population level.

Strengths

To our knowledge, this is the largest patient sample size for a systematic review and

meta-analysis on the use of Ivermectin for COVID-19. This study integrates data of

approximately 17,000 patients from 52 studies- both trials and observational, conducted globally.

Additionally, we obtained robust evidence by conducting various subgroup analyses. One

noteworthy Ivermectin study, a large clinical trial[48], was recently withdrawn on grounds of

ethical misconduct. Its strongly positive findings accounted for significant effect size in the

meta-analyses published so far. This has led us to question the existing conclusions regarding the

efficacy of this drug. Ours would be the first meta-analysis that excluded the flawed study to

clear the air regarding the effect of Ivermectin in COVID-19 for a stronger empirical evidence of

Ivermectin's efficacy. We also excluded studies which did not meet the rigor of true RCTs in the

' RCTs' subgroup. We used GRADE-pro tool[55] to rate certainty of evidence for all outcomes,

which was not done in past to provide more insight. The GRADE framework is known to be the

most widely used assessment to rate quality of evidence[55]. Sensitivity analyses were performed

with the aim of testing the robustness of results. Moreover, we performed pooled analyses to

incorporate data from uncontrolled studies.

Limitations

Our results are to be interpreted carefully bearing in mind that we included several non-

peer-reviewed articles to obtain the latest data. We cannot preclude the possibility of unreported

biases and confounders that could have been recognized by a peer-review process. Furthermore,

there was significant heterogeneity in treatment protocols used for dosage, duration, route of

administration in interventional and control group. Our analyses may not have accounted for

confounding by concomitant therapy. We only analyzed the mortality outcome as per Cochrane's

strict selection criteria for Ivermectin monotherapy compared to standard of care/placebo. Patient

demographics and outcome measures varied among different studies. Few studies documented

the inclusion of patients <18 years of age. However, the mean/median and dispersion values

consistently suggested a predominantly adult population. The clinical classification for severity

was inconsistent across the included studies. Most studies were conducted on patients with mild

/moderate presentation, which limits the generalizability of our results.

Apart from this, there was insufficient data regarding the time of treatment in the course

of the disease, hence inferences could not be made in that regard. We could not confirm adequate

control-matching in some observational studies. We advise discretion in interpretation of our

results for adverse-event rate since most of the reported adverse-effects could not be measured

objectively by investigators. Because most of the studies were conducted in developing nations,

not everyone underwent RT-PCR testing owing to limited resources; clinical diagnosis was used

instead. Even though RT-PCR is the gold standard for diagnosis, it is subject to its limitations.

By virtue of its design, we postulate that this meta-analysis formulated with a random-effects

model may have addressed some of the heterogeneity stemming from the above factors. Lastly,

we must acknowledge the subjective nature of the GRADE tool used to evaluate the level of

evidence[55].

Current status of Ivermectin

In February 2021, the NIH declared that it neither recommends for or against using

Ivermectin for COVID-19[139] due to inadequate data. For further guidance, they require evidence

from larger, well-designed and well-executed trials. As of March 5,2021, the FDA has warned

people against using Ivermectin for COVID-19[140], specifically against self-medicating with

veterinary Ivermectin formulations[140,141]. They are yet to review the evidence but have initiated a

preliminary research. In late March, the EMA (European Medicines Agency) stated that

Ivermectin cannot be recommended for the prevention or treatment of COVID-19 outside

clinical trials[142]. Similarly, the WHO suggested limiting Ivermectin use to clinical trials until

more data is available[143]. A large phase 3 clinical trial evaluating the use of Ivermectin in

COVID-19 patients with mild to moderate symptoms is yet to be concluded[144]. The NIH, FDA

,CDC, EMA and several other important government and private sector bodies will collaborate

on this "Master protocol" titled ACTIV-6 that focuses on rigorous testing of up to seven

repurposed drugs[145]. Recently, the CDC issued warning against the use of non-prescription

Ivermectin as well as the ingestion of Ivermectin-containing topical or veterinary products and

advised seeking immediate medical care for any adverse effects arising out of such events[146].

Conclusion

In summary, based on updated evidence, benefit of Ivermectin as monotherapy or in

combination treatment for lowering the COVID-19 associated mortality is inconclusive due to

lack of high-quality RCTs. Ivermectin combination therapy may play a role in controlling the

viral replication and preventing the need for hospitalization. Using well-designed larger

observational studies[147,148] and clinical trials, we need to further investigate its efficacy, its ideal

dosage and timing in the disease course, drug interactions and possible synergistic drug

combinations to achieve maximum benefit. We also need to evaluate the benefit of Ivermectin

for treating the various emerging strains as well as its role in vaccinated individuals. We propose

pragmatic practice embedded platform trials[149] to test this and other re-purposed and novel

therapies specifically in severe COVID-19 patients and other critically ill patients. We

recommend the medical practitioners to exercise caution until further evidence is available and

use their best clinical judgement while prescribing Ivermectin in COVID-19 patients.

References:

1. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed.* 2020;91(1):157-160.
2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis.* 2020;20(5):533-534.
3. Domecq JP, Lal A, Sheldrick CR, et al. Outcomes of Patients With Coronavirus Disease 2019 Receiving Organ Support Therapies: The International Viral Infection and Respiratory Illness Universal Study Registry. *Critical Care Medicine.* 9000;Online First.
4. Bansal V, Singh R, Bhurwal A, Rathore S, Kashyap R. 117: Obesity Is a Risk Factor for Increased COVID-19 Severity: A Systemic Review and Meta-Regression. *Critical Care Medicine.*49(1):43.
5. Menon T, Gandhi SAQ, Tariq W, et al. Impact of Chronic Kidney Disease on Severity and Mortality in COVID-19 Patients: A Systematic Review and Meta-analysis. *Cureus.* 2021;13(4):e14279.
6. Menon T, Sharma R, Kataria S, et al. The Association of Acute Kidney Injury With Disease Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis. *Cureus.* 2021;13(3):e13894.
7. Singh R, Shiza ST, Saadat R, Dawe M, Rehman U. Association of Guillain-Barre Syndrome With COVID-19: A Case Report and Literature Review. *Cureus.* 2021;13(3):e13828.
8. Menon T, Sharma R, Earthineni G, et al. Association of Gastrointestinal System With Severity and Mortality of COVID-19: A Systematic Review and Meta-Analysis. *Cureus.* 2021;13(2):e13317.
9. Razonable RR, Pennington KM, Meehan AM, et al. A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease 2019 in the Hospital Setting. *Mayo Clinic Proceedings.* 2020;95(7):1467-1481.
10. Rathore SS, Rojas GA, Sondhi M, et al. *Myocarditis associated with Covid-19 disease: a systematic review of published Case reports and Case series.* Preprints; 2021/02/01/ 2021.
11. Sheraton M, Deo N, Kashyap R, Surani S. A Review of Neurological Complications of COVID-19. *Cureus.* 2020;12(5):e8192.
12. Khan H, Sabzposh H, Deshpande S, Kashyap R. Pregnancy during COVID-19 pandemic - Maternal and neonatal outcomes: A concise review. *International Journal of Academic Medicine.* 2020;6(4):287-293.
13. Shah K, Mann S, Singh R, Bangar R, Kulkarni R. Impact of COVID-19 on the Mental Health of Children and Adolescents. *Cureus.* 2020;12(8):e10051.
14. Sheraton M, Deo N, Dutt T, Surani S, Hall-Flavin D, Kashyap R. Psychological effects of the COVID 19 pandemic on healthcare workers globally: A systematic review. *Psychiatry Res.* 2020;292:113360.
15. Singh R, Kashyap R, Hutton A, Sharma M, Surani S. A Review of Cardiac Complications in Coronavirus Disease 2019. *Cureus.* 2020;12(5):e8034.
16. Bhalala U, Gist K, Tripathi S, et al. 145: Pediatric COVID-19: A Report From Viral Infection and Respiratory Illness Universal Study (VIRUS). *Critical Care Medicine.*49(1):58.
17. Tripathi S, Gist K, Chiotos K, et al. 61: Risk Factors for Severe COVID-19 Illness in Children: Analysis of the VIRUS: COVID-19 Registry. *Critical Care Medicine.*49(1):32.
18. Md Insiat Islam R. Current Drugs with Potential for Treatment of COVID-19: A Literature Review. *J Pharm Pharm Sci.* 2020;23(1):58-64.

19. Gilzad-Kohan H, Jamali F. Anti-Inflammatory Properties of Drugs Used to Control
COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-
Converting Enzyme-2. *J Pharm Pharm Sci.* 2020;23:259-277.
20. Bansal V, Mahapure KS, Mehra I, et al. Mortality Benefit of Convalescent Plasma in
COVID-19: A Systematic Review and Meta-Analysis. *Front Med (Lausanne).*
2021;8:624924.
21. Singh R, Rathore SS, Khan H, et al. Mortality and Severity in COVID-19 Patients on
ACEIs & ARBs-A Meta-Regression Analysis. *medRxiv.* 2021.
22. Mahmud S, Nagraj S, Karia R, et al. 140: Efficacy and Safety of Tocilizumab in
Hospitalized COVID-19 Patients: A Systematic Review. *Critical Care Medicine.*
2021;49(1):55.
23. Bansal V, Mahapure KS, Bhurwal A, et al. Mortality Benefit of Remdesivir in COVID-19:
A Systematic Review and Meta-Analysis. *Front Med (Lausanne).* 2020;7:606429.
24. Crump A. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and
exceed expectations. *J Antibiot (Tokyo).* 2017;70(5):495-505.
25. Sharun K, Dhama K, Patel SK, et al. Ivermectin, a new candidate therapeutic against
SARS-CoV-2/COVID-19. *Ann Clin Microbiol Antimicrob.* 2020;19(1):23.
26. Lundberg L, Pinkham C, Baer A, et al. Nuclear import and export inhibitors alter capsid
protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis
Virus replication. *Antiviral Res.* 2013;100(3):662-672.
27. Tay MY, Fraser JE, Chan WK, et al. Nuclear localization of dengue virus (DENV) 1-4
non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor
Ivermectin. *Antiviral Res.* 2013;99(3):301-306.
28. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific
inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-
1 and dengue virus. *Biochem J.* 2012;443(3):851-856.
29. DiNicolantonio JJ, Barroso J, McCarty M. Ivermectin may be a clinically useful anti-
inflammatory agent for late-stage COVID-19. *Open Heart.* 2020;7(2).
30. Zhang X, Song Y, Ci X, et al. Ivermectin inhibits LPS-induced production of inflammatory
cytokines and improves LPS-induced survival in mice. *Inflamm Res.* 2008;57(11):524-
529.
31. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug
ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res.*
2020;178:104787.
32. Gorial FI, Mashhadani S, Sayaly HM, et al. Effectiveness of Ivermectin as add-on
Therapy in COVID-19 Management (Pilot Trial). *medRxiv.* 2020.
33. Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin Is
Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease
2019: The Ivermectin in COVID Nineteen Study. *Chest.* 2021;159(1):85-92.
34. Bhattacharya R, Ray I, Mukherjee R, Chowdhury S, Kulasreshtha M, Ghosh R.
Observational Study on Clinical Features, Treatment and Outcome of Covid 19 in a
Tertiary Care Centre in India - a Retrospective Case Series. *International Journal of
Scientific Research.* 2020;9(10):1-3.
35. Chowdhury AMM, Shahbaz M, Karim MR, Islam J, Dan G, He SX. A Comparative Study
on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19
Patients. *Eurasian Journal of Medicine and Oncology.* 2021;5(1):63-70.
36. Mega ER. Latin America's embrace of an unproven COVID treatment is hindering drug
trials. *Nature.* 2020;586(7830):481-482.
37. Trial Site Staff. Beyond The Roundup | First EU Nation To Approve Ivermectin For
Covid-19. https://trialsitenews.com/beyond-the-roundup-first-eu-nation-to-approve-
ivermectin-for-covid-19/. Published January 30, 2021. Accessed 02.14.2021.

38. Nayar S, Khanna P, Anand P, et al. Ivermectin in Covid-19: Review of the Current
Evidence. *The Indian Practitioner.* 2021;74(3):27-33.
39. AIIMS/ ICMR-COVID-19 National Task Force/Joint Monitoring Group (Dte.GHS).
CLINICAL GUIDANCE FOR MANAGEMENT OF ADULT COVID-19 PATIENTS. Ministry
of Health & Family Welfare, Government of India.
https://www.mohfw.gov.in/pdf/COVID19ManagementAlgorithm22042021v1.pdf.
Published 2021. Updated 04/22/2021. Accessed 04/25/2021.
40. Chamie-Quintero JJ, Hibberd J, Scheim D. Sharp reductions in COVID-19 case fatalities
and excess deaths in Peru in close time conjunction, state-by-state, with ivermectin
treatments. *State-By-State, with Ivermectin Treatments (January 12, 2021).* 2021.
41. Yagisawa M, Foster PJ, Hanaki H, Ōmura S. Global trends in clinical studies of
ivermectin in COVID-19. *THE JAPANESE JOURNAL OF ANTIBIOTICS.* 2021;74:1.
42. Cadegiani FA, Goren A, Wambier CG, McCoy J. Early COVID-19 Therapy with
Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient
Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated
Patients. *medRxiv.* 2020.
43. Lima-Morales R, Mendez-Hernandez P, Flores YN, et al. Effectiveness of a multidrug
therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to
prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala,
Mexico. *Int J Infect Dis.* 2021;105:598-605.
44. Niaee MS, Gheibi N, Namdar P, et al. Ivermectin as an adjunct treatment for hospitalized
adult COVID-19 patients: A randomized multi-center clinical trial. *Research Square.*
2020.
45. Mahmud R, Rahman MM, Alam I, et al. Ivermectin in combination with doxycycline for
treating COVID-19 symptoms: a randomized trial. *J Int Med Res.*
2021;49(5):3000605211013550.
46. Ravindra G, Chitra L, Madhur M, et al. Retrospective Assessment of Treatments of
Hospitalized Covid-19 Patients. *medRxiv.* 2021.
47. Samaha AA, Mouawia H, Fawaz M, et al. Effects of a Single Dose of Ivermectin on Viral
and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical
Trial in Lebanon. *Viruses.* 2021;13(6).
48. Elgazzar A, Eltaweel A, Youssef SA, Hany B, Hafez M, Moussa H. Efficacy and Safety
of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic. *Research Square.*
2020.
49. The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version
5.4 for Windows. Oxford, England: The Cochrane Collaboration.
https://training.cochrane.org/online-learning/core-software-cochrane-
reviews/revman/revman-5-download. Published 2020. Accessed 01/31/2021.
50. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version
3. Biostat, Englewood, NJ 2013. https://www.meta-
analysis.com/index.php?cart=BBFA4702757. Published 2013. Accessed 01/31/2021.
51. Higgins JPT, Thomas J, Chandler J, et al. *Cochrane handbook for systematic reviews of
interventions.* John Wiley & Sons; 2019.
52. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for
assessing risk of bias in randomised trials. *BMJ.* 2011;343:d5928.
53. Balk EM, Bonis PA, Moskowitz H, et al. Correlation of quality measures with estimates of
treatment effect in meta-analyses of randomized controlled trials. *Jama.*
2002;287(22):2973-2982.
54. National Heart L, and Blood Institute,. Development and Use of Study Quality
Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-
tools. Updated 04/14/2021. Accessed 04/14/2021, 2020.

55.   Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of
evidence and the strength of recommendations using the GRADE approach. *Updated*
October. 2013;2013.
56.   Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use
Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting.
Available at SSRN 3734478. 2020.
57.   Ahmed S, Karim MM, Ross AG, et al. A five-day course of ivermectin for the treatment of
COVID-19 may reduce the duration of illness. *Int J Infect Dis.* 2021;103(Feb):214-216.
58.   Ahsan T, Rani B, Siddiqui R, et al. Clinical Variants, Characteristics, and Outcomes
Among COVID-19 Patients: A Case Series Analysis at a Tertiary Care Hospital in
Karachi, Pakistan. *Cureus.* 2021;13(4):e14761.
59.   Robin RC, Alam RF, Saber S, Bhiuyan E, Murshed R, Alam MT. A Case Series of 100
COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline.
Journal of Bangladesh College of Physicians and Surgeons. 2020;38(0):10-15.
60.   Babalola OE, Bode CO, Ajayi AA, et al. Ivermectin shows clinical benefits in mild to
moderate COVID19: A randomised controlled double-blind, dose-response study in
Lagos. *QJM.* 2021.
61.   Biber A, Mandelboim M, Harmelin G, et al. Favorable outcome on viral load and culture
viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-
19, A double-blind, randomized placebo-controlled trial. *medRxiv.* 2021.
62.   Budhiraja S, Soni A, Jha V, et al. Clinical Profile of First 1000 COVID-19 Cases Admitted
at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience.
medRxiv. 2020.
63.   Shah Bukhari KH, Asghar A, Perveen N, et al. Efficacy of Ivermectin in COVID-19
Patients with Mild to Moderate Disease. *medRxiv.* 2021.
64.   Camprubi D, Almuedo-Riera A, Marti-Soler H, et al. Lack of efficacy of standard doses of
ivermectin in severe COVID-19 patients. *PLoS One.* 2020;15(11):e0242184.
65.   Carvallo H. Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid
19 - Study Results - ClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/results/NCT04425863?view=results. Published 2020.
Updated 10/19/2020. Accessed 02/12/2021.
66.   Chaccour C, Casellas A, Blanco-Di Matteo A, et al. The effect of early treatment with
ivermectin on viral load, symptoms and humoral response in patients with non-severe
COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.
EClinicalMedicine. 2021;32(100720):100720.
67.   Zeeshan Khan Chachar A, Ahmad Khan K, Asif M, Tanveer K, Khaqan A, Basri R.
Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients. *International Journal of*
Sciences. 2020;9(09):31-35.
68.   Chahla RE, Ruiz LM, Mena T, et al. Cluster Randomised Trials-Ivermectin Repurposing
For COVID-19 Treatment Of Outpatients With Mild Disease In Primary Health Care
Centers. *Research Square.* 2021.
69.   Elalfy H, Besheer T, El-Mesery A, et al. Effect of a combination of nitazoxanide, ribavirin,
and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild
COVID-19. *J Med Virol.* 2021;93(5):3176-3183.
70.   Espitia-Hernandez G, Munguia L, Diaz-Chiguer D, López-Elizalde R, Jimenez-Ponce F.
Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19
infected patients: A proof of concept study. *Biomedical Research.* 2020;31(5):129-133.
71.   Galan LEB, Santos NMD, Asato MS, et al. Phase 2 randomized study on chloroquine,
hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of
SARS-CoV-2 infection. *Pathog Glob Health.* 2021;115(4):235-242.

72.   Gonzalez JLB, González Gámez M, Enciso EAM, et al. Efficacy and safety of Ivermectin
and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled
trial. *medRxiv.* 2021.
73.   Guzmán MJM, Castillo-Gonzalez A, Gonzalez JLB, et al. Factors associated with
increased mortality in critically ill COVID-19 patients in a Mexican public hospital: the
other faces of health system oversaturation. *medRxiv.* 2021.
74.   Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulamir AS. Controlled
randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19
patients in Baghdad, Iraq. *medRxiv.* 2020:2020.2010.2026.20219345.
75.   Hussain SMA, Shuayb M, Rahman M. Outcome of ivermectin and doxycycline in cancer
patients with COVID-19: A positive experience in Bangladesh. *International Journal of*
Molecular & Immuno Oncology. 2021;6(1):27-29.
76.   Release HP. Kovid-19 - Huvemek® Phase 2 clinical trial -. Huvepharma
https://huvemec.bg/covid-19-huvemec-klinichno-izpitanie/za-isledvaneto/. Updated
03/25/2021. Accessed 05/22/2021.
77.   Khan MSI, Khan MSI, Debnath CR, et al. Ivermectin Treatment May Improve the
Prognosis of Patients With COVID-19. *Arch Bronconeumol (Engl Ed).* 2020;56(12):828-
830.
78.   Ravikirti, Roy R, Pattadar C, et al. Ivermectin as a potential treatment for mild to
moderate COVID-19 – A double blind randomized placebo-controlled trial. *medRxiv.*
2021.
79.   Kishoria N, Mathur SL, Parmar V, et al. IVERMECTIN AS ADJUVANT TO
HYDROXYCHOLOROQUINE IN PATIENTS RESISTANT TO STANDARD
TREATMENT FOR SARS-CoV-2: RESULTS OF AN OPEN-LABEL RANDOMIZED
CLINICAL STUDY. *Paripex Indian Journal of Research.* 2020;9(8):1-4.
80.   Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high-dose ivermectin in
adults with COVID-19: A proof-of-concept randomized trial. *EClinicalMedicine.* 2021;37.
81.   Lopez-Medina E, Lopez P, Hurtado IC, et al. Effect of Ivermectin on Time to Resolution
of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. *Jama.*
2021;325(14):1426-1435.
82.   Pierre L, Christine F. Ivermectin and COVID-19 in Care Home: Case Report. *Journal of*
Infectious Diseases and Epidemiology. 2021;7(4):1-4.
83.   Mohan A, Tiwari P, Suri T, et al. Ivermectin in mild and moderate COVID-19 (RIVET-
COV): a randomized, placebo-controlled trial. *Research Square.* 2021.
84.   Morgenstern J, Redondo JN, De León A, et al. The use of compassionate Ivermectin in
the management of symptomatic outpatients and hospitalized patients with clinical
diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta
Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020. *J Clin Trials.*
2020;11(S9:1000002):1-4.
85.   Mourya S, Thakur AS, Hada DS, Kulshreshtha VS, Sharma Y. Comparative Analytical
Study of Two Different Drug Regimens in Treatment of Covid 19 Positive Patients in
Index Medical College Hospital and Research Center, Indore, India. *International Journal*
of Health and Clinical Research. 2021;4(6):265-267.
86.   Núñez AC, Yuca GG, Cervantes JML, Murcia APR, Juárez MAO, Martínez JJ.
Therapeutic Efficacy of Ivermectin as an Adjuvant in the Treatment of Patients with
COVID-19 Study conducted at the Social Security Institute for Workers of the State of
Chiapas, ISSTECH, Mexico. *International Journal of Innovative Science and Research*
Technology. 2020;5(7):211-215.
87.   Podder CS, Chowdhury N, Sina MI, Haque WMMU. Outcome of ivermectin treated mild
to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study.
IMC Journal of Medical Science. 2020;14(2:002):11-18.

88. Okumus N, Demirturk N, Cetinkaya RA, et al. Evaluation of the effectiveness and safety
of adding ivermectin to treatment in severe COVID-19 patients. *BMC Infect Dis.*
2021;21(1):411.
89. Pott-Junior H, Bastos Paoliello MM, Miguel AQC, et al. Use of ivermectin in the
treatment of Covid-19: A pilot trial. *Toxicol Rep.* 2021;8(0):505-510.
90. Rahman MA, Iqbal SA, Islam MA, Niaz MK, Hussain T, Siddiquee TH. Comparison of
viral clearance between ivermectin with doxycycline and hydroxychloroquine with
azithromycin in COVID-19 patients. *Journal of Bangladesh College of Physicians and*
Surgeons. 2020;38:5-9.
91. Shahbaznejad L, Davoudi A, Eslami G, et al. Effects of Ivermectin in Patients With
COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial. *Clin Ther.*
2021.
92. Soto-Becerra P, Culquichicón C, Hurtado-Roca Y, Araujo-Castillo RV. Real-world
effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized
COVID-19 patients: results of a target trial emulation using observational data from a
nationwide healthcare system in Peru. *medRxiv.* 2020.
93. Spoorthi V, Sasank S. Utility of ivermectin and doxycycline combination for the treatment
of SARS-CoV2. *IAIM.* 2020;7(10):177-182.
94. Abd-Elsalam S, Noor RA, Badawi R, et al. Clinical study evaluating the efficacy of
ivermectin in COVID-19 treatment: A randomized controlled study. *J Med Virol.*
2021;93(10):5833-5838.
95. Aref ZF, Bazeed S, Hassan MH, et al. Clinical, Biochemical and Molecular Evaluations
of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper
Respiratory Symptoms of Mild COVID-19. *Int J Nanomedicine.* 2021;16:4063-4072.
96. Vallejos J, Zoni R, Bangher M, et al. Ivermectin to prevent hospitalizations in patients
with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled
trial. *BMC Infect Dis.* 2021;21(1):635.
97. Hazan S, Dave S, Gunaratne AW, et al. Effectiveness of Ivermectin-Based Multidrug
Therapy in Severe Hypoxic Ambulatory COVID-19 Patients. *medRxiv.* 2021.
98. Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ivermectin as add
on treatment in COVID 19: A systematic review and meta-analysis. *J Pharm Pharm Sci.*
2020;23:462-469.
99. Hill A, Abdulamir A, Ahmed S, et al. Meta-analysis of randomized trials of ivermectin to
treat SARS-CoV-2 infection. *Research Square.* 2021.
100. Hill A, Garratt A, Levi J, et al. Erratum: Expression of Concern: "Meta-analysis of
Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection". *Open Forum Infect*
Dis. 2021;8(8):ofab394.
101. Lawrie T. *Ivermectin reduces the risk of death from COVID-19 -a rapid review and meta-*
analysis in support of the recommendation of the Front Line COVID-19 Critical Care
Alliance. (Latest version v1.2 - 6 Jan 2021). 2021.
102. Nardelli P, Zangrillo A, Sanchini G, et al. Crying wolf in time of Corona: the strange case
of ivermectin and hydroxychloroquine. Is the fear of failure withholding potential life-
saving treatment from clinical use? *Signa Vitae.* 2021;1:2.
103. Kow CS, Merchant HA, Mustafa ZU, Hasan SS. The association between the use of
ivermectin and mortality in patients with COVID-19: a meta-analysis. *Pharmacol Rep.*
2021:1-7.
104. Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for Prevention and Treatment of
COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis
to Inform Clinical Guidelines. *Am J Ther.* 2021.

105. Kory P, Meduri GU, Varon J, Iglesias J, Marik PE. Review of the Emerging Evidence
Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.
American Journal of Therapeutics. 2021;28(3):e299-e318.
106. Hariyanto TI, Halim DA, Rosalind J, Gunawan C, Kurniawan A. Ivermectin and outcomes
from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical
trial studies. *Reviews in Medical Virology.* 2021;e2265:1-15.
107. British Ivermectin Recommendation Development. The BIRD Recommendation on the
Use of Ivermectin for Covid-19. https://www.francesoir.fr/sites/francesoir/files/media-
icons/bird-proceedings-02-03-2021-v151.pdf. Published 2021. Accessed 04.01.2021.
108. Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of
pharmacological interventions for the treatment of COVID-19: A systematic review and
network meta-analysis. *PLoS Med.* 2020;17(12):e1003501.
109. Castañeda-Sabogal A, Chambergo-Michilot D, Toro-Huamanchumo CJ, Silva-Rengifo
C, Gonzales-Zamora J, Barboza JJ. Outcomes of Ivermectin in the treatment of COVID-
19: a systematic review and meta-analysis. *medRxiv.* 2021:2021.2001.2026.21250420.
110. Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for
the treatment of COVID-19: A systematic review and meta-analysis of randomized
controlled trials. *medRxiv.* 2021.
111. Popp M, Stegemann M, Metzendorf MI, et al. Ivermectin for preventing and treating
COVID-19. *Cochrane Database Syst Rev.* 2021;7(7):CD015017.
112. NIH. Corticosteroids | COVID-19 Treatment Guidelines.
https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/corticoster
oids/. Published 2021. Updated 08/04/2021. Accessed 08/25/2021.
113. Derbyshire E, Delange J. COVID-19: is there a role for immunonutrition, particularly in
the over 65s? *BMJ Nutr Prev Health.* 2020;3(1):100-105.
114. Bauer SR, Kapoor A, Rath M, Thomas SA. What is the role of supplementation with
ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-
19? *Cleve Clin J Med.* 2020.
115. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. WHO.
https://covid19.who.int/. Updated 02.14.2021. Accessed 02.14.2021.
116. Chamie-Quintero J, Hibberd JA, Scheim D. Ivermectin for COVID-19 in Peru: 14-fold
reduction in nationwide excess deaths, p=. 002 for effect by state, then 13-fold increase
after ivermectin use restricted. 2021.
117. Abate SM, Ahmed Ali S, Mantfardo B, Basu B. Rate of Intensive Care Unit admission
and outcomes among patients with coronavirus: A systematic review and Meta-analysis.
PLoS One. 2020;15(7):e0235653.
118. Elsayed HH, Hassaballa AS, Ahmed TA, Gumaa M, Sharkawy HY. Variation in outcome
of invasive mechanical ventilation between different countries for patients with severe
COVID-19: a systematic review and meta-analysis. 2020.
119. Richardson S. Presenting characteristics, comorbidities, and outcomes among 5700
patients hospitalized with COVID-19 in the New York City area (published online ahead
of print, 2020 Apr 22). *Jama.*
120. Jaspersen D. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention
and management. *Drug Saf.* 2000;22(3):237-249.
121. Yousaf Z, Al-Shokri SD, Al-Soub H, Mohamed MFH. COVID-19-associated SIADH: a
clue in the times of pandemic! *Am J Physiol Endocrinol Metab.* 2020;318(6):E882-E885.
122. Mahmud R. Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed
Covid-19 Infection. Dhaka Medical College Bangladesh.
https://clinicaltrials.gov/ct2/show/study/NCT04523831. Published 2020. Updated
October 9, 2020. Accessed 02.14.2021.

123.   Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 -
885   Final Report. *N Engl J Med.* 2020;383(19):1813-1826.

886   124.   Group WHOREAfC-TW, Sterne JAC, Murthy S, et al. Association Between
887   Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients
888   With COVID-19: A Meta-analysis. *Jama.* 2020;324(13):1330-1341.

889   125.   Datta SD, Talwar A, Lee JT. A Proposed Framework and Timeline of the Spectrum of
890   Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health
891   Implications. *Jama.* 2020;324(22):2251-2252.

892   126.   Boscolo-Rizzo P, Guida F, Polesel J, et al. Sequelae in adults at 12 months after mild-to-
893   moderate coronavirus disease 2019 (COVID-19). *Int Forum Allergy Rhinol.* 2021.

894   127.   Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med.*
895   2021;27(4):601-615.

896   128.   Gunster C, Busse R, Spoden M, et al. 6-month mortality and readmissions of
897   hospitalized COVID-19 patients: A nationwide cohort study of 8,679 patients in
898   Germany. *PLoS One.* 2021;16(8):e0255427.

899   129.   Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
900   Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases
901   From the Chinese Center for Disease Control and Prevention. *Jama.*
902   2020;323(13):1239-1242.

903   130.   CDC. Interim clinical guidance for management of patients with confirmed coronavirus
904   disease (COVID-19). Centers for Disease Control Prevention.
905   https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-
906   patients.html. Published 2020. Updated 02/12/2021. Accessed 06/19/2021.

907   131.   Group RC. Convalescent plasma in patients admitted to hospital with COVID-19
908   (RECOVERY): a randomised controlled, open-label, platform trial. *Lancet.*
909   2021;397(10289):2049-2059.

910   132.   Janiaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treatment
911   With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-
912   analysis. *Jama.* 2021;325(12):1185-1195.

913   133.   Garibaldi BT, Wang K, Robinson ML, et al. Comparison of Time to Clinical Improvement
914   With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. *JAMA
915   Netw Open.* 2021;4(3):e213071.

916   134.   Bayram N, Ozsaygili C, Sav H, et al. Susceptibility of severe COVID-19 patients to rhino-
917   orbital mucormycosis fungal infection in different clinical manifestations. *Jpn J
918   Ophthalmol.* 2021;65(4):515-525.

919   135.   Festic E, Kor DJ, Gajic O. Prevention of acute respiratory distress syndrome. *Curr Opin
920   Crit Care.* 2015;21(1):82-90.

921   136.   Gajic O, Dabbagh O, Park PK, et al. Early identification of patients at risk of acute lung
922   injury: evaluation of lung injury prediction score in a multicenter cohort study. *Am J
923   Respir Crit Care Med.* 2011;183(4):462-470.

924   137.   Lat I, Coopersmith CM, De Backer D, et al. The Surviving Sepsis Campaign: Fluid
925   Resuscitation and Vasopressor Therapy Research Priorities in Adult Patients. *Crit Care
926   Med.* 2021;49(4):623-635.

927   138.   Youkee D, Hulme W, Roberts T, Daniels R, Nutbeam T, Keep J. Time Matters: Antibiotic
928   Timing in Sepsis and Septic Shock. *Crit Care Med.* 2016;44(10):e1016-1017.

929   139.   National Institutes of Health. Ivermectin | COVID-19 Treatment Guidelines. National
930   Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/antiviral-
931   therapy/ivermectin/. Published 2020. Updated February 11, 2021. Accessed 02.14.2021.

932   140.   FDA. FAQ: COVID-19 and Ivermectin Intended for Animals | FDA. FDA.
933   https://www.fda.gov/animal-veterinary/product-safety-information/faq-covid-19-and-

ivermectin-intended-animals. Published 2020. Updated 12/16/2020. Accessed
02.14.2021.
141. FDA. Why You Should Not Use Ivermectin to Treat or Prevent COVID-19 | FDA.
https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-
treat-or-prevent-covid-19. Published 2021. Updated 03.05.2021. Accessed 04.10.2021.
142. European Medicines Agency. EMA advises against use of ivermectin for the prevention
or treatment of COVID-19 outside randomised clinical trials | European Medicines
Agency. https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin-
prevention-treatment-covid-19-outside-randomised-clinical-trials. Published 2021.
Updated 03.22.2021. Accessed 04.10.2021.
143. World Health Organization. WHO advises that ivermectin only be used to treat COVID-
19 within clinical trials. https://www.who.int/news-room/feature-stories/detail/who-
advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials. Published
2021. Updated 03/31/2021. Accessed 08/25/2021.
144. ACTIV-6: COVID-19 Study of Repurposed Medications.
https://clinicaltrials.gov/ct2/show/NCT04885530. Published 2021. Updated 08/30/2021.
Accessed 09/02/2021.
145. National Institutes of Health. NIH to launch public-private partnership to speed COVID-
19 vaccine and treatment options. https://www.nih.gov/news-events/news-releases/nih-
launch-public-private-partnership-speed-covid-19-vaccine-treatment-options. Updated
04/17/2020. Accessed 08/25/2021.
146. CDC Health Alert Network. CDCHAN-00449: Rapid Increase in Ivermectin Prescriptions
and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to
Prevent or Treat COVID-19.
https://emergency.cdc.gov/han/2021/han00449.asp?ACSTrackingID=USCDC_511-
DM64535&ACSTrackingLabel=HAN%20449%20-
%20General%20Public&deliveryName=USCDC_511-DM64535. Published 2021.
Updated 08/26/2021. Accessed 09/03/2021.
147. Walkey AJ, Sheldrick RC, Kashyap R, et al. Guiding Principles for the Conduct of
Observational Critical Care Research for Coronavirus Disease 2019 Pandemics and
Beyond: The Society of Critical Care Medicine Discovery Viral Infection and Respiratory
Illness Universal Study Registry. *Crit Care Med.* 2020;48(11):e1038-e1044.
148. Walkey AJ, Kumar VK, Harhay MO, et al. The Viral Infection and Respiratory Illness
Universal Study (VIRUS): An International Registry of Coronavirus 2019-Related Critical
Illness. *Crit Care Explor.* 2020;2(4):e0113.
149. FDA. FDA experts discuss COVID-19 therapeutic clinical trials | American Medical
Association. AMA Webinar Series. https://www.ama-assn.org/delivering-care/public-
health/fda-experts-discuss-covid-19-therapeutic-clinical-trials. Updated 03/17/2021.
Accessed 04/15/2021.

Figure and Table Legends:

Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow—

study inclusion. ICU: Intensive Care Unit, CDC: Centers for Disease Control and

Prevention, RCT: Randomized controlled trial, WHO: World Health Organization

Figure 2: Meta-analysis for Ivermectin use and overall Mortality

Figure 3: Subgroup analysis for Ivermectin use and mortality by study design and

hospitalized patients

Figure 4 Effect of Ivermectin Monotherapy compared with Placebo/Standard of Care in

RCTs as per Cochrane's criteria

Figure 5: Meta-analysis for Ivermectin use and need for ICU admission, mechanical

ventilation and Adverse events

Figure 6: Meta-analysis for Ivermectin use and need for Viral Clearance, Time to achieve

viral clearance, Need for hospitalization and Duration of hospital stay

e-figure 1 Sensitivity analysis excluding Lima-morales et al: Mortality in Clinical trials

e-figure 2 Sensitivity analysis excluding Vallejos et al: Mortality in Therapeutic RCTs:

Mild-Moderate COVID-19

e-figure 3 Sensitivity analysis excluding Soto-Becerra et al: Mortality in observational

studies

e-figure 4 Sensitivity analysis excluding Soto-Becerra et al: Mortality in hospitalized

patients-Overall

e-figure 5 Sensitivity analysis excluding Abd-elsalam et al: Mortality in hospitalized

patients by study design RCTs: Mild-Moderate COVID-19

e-figure 29 Funnel Plot duration of Hospital stay

e-figure 30 Funnel Plot Incidence of Viral Clearance

e-figure 31 Funnel Plot Time to achieve viral clearance

e-table 1. Study characteristic table for all included studies

e-table 2. Cochrane Risk of bias assessment of the trials included in the study

e-table 3. Correlation of quality measures with estimates of treatment effects assessment of
the trials those were included in the study

e-table 4. NIH quality assessment Tool for case series included in the study

e-table 5. NIH Quality Assessment of Case-Control Studies

e-table 6. NIH Quality Assessment of Observational Cohort and Cross-Sectional Studies

e-table 7. Certainty of the evidence (GRADE) Profile at Outcome Level

e-table 8. Ongoing clinical trials

1033

1034   **Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow—**

1035   **study inclusion. ICU: Intensive Care Unit, CDC: Centers for Disease Control and**

1036   **Prevention, RCT: Randomized controlled trial, WHO: World Health Organization**

1037   **Figure 2: Meta-analysis for Ivermectin use and overall Mortality**

1038   **Figure 2A: Mortality Overall**

1039

1040   **Figure 2B Sensitivity analysis Mortality Overall excluding Soto-Becerra et al**

1041

1042   **Figure 3: Subgroup analysis for Ivermectin use and mortality by study design and**
1043   **hospitalized patients**

1044   **Figure 3A Subgroup analysis by study designs- Mortality in Clinical trials**

1045

1046   **Figure 3B Subgroup analysis by study designs- Mortality in Therapeutic RCTs: Mild-**
1047   **Moderate COVID-19**

1048

1049

1050

1051   **Figure 3C Subgroup analysis by study designs- Mortality in Therapeutic RCTs:**

1052   **Severe/Critical COVID-19**

1053

1054   **Figure 3D: Subgroup analysis by study designs- Mortality in observational studies**

1055

1056   **Figure 3E: Mortality in hospitalized patients-Overall**

1057

1058   **Figure 3F: Mortality in hospitalized patients by study design RCTs-Mild-Moderate COVID-**
1059   **19**

1060

1061   **Figure 3G: Mortality in hospitalized patients by study design RCTs- Severe/Critical COVID-**
1062   **19**

1063

1064   **Figure 3H: Mortality in hospitalized patients by study design observational studies**

1065

1066

1067 **Figure 4 Effect of Ivermectin Monotherapy compared with Placebo/Standard of Care in RCTs**
1068 **as per Cochrane's criteria**

1069

1070 **Figure 5: Meta-analysis for Ivermectin use and need for ICU admission, mechanical**
1071 **ventilation and Adverse events**

1072 **Figure 5A Need for ICU admission**

1073

1074 **Figure 5B Sensitivity Analysis excluding Galan et al : Need for ICU admission**

1075

     Figure 5C Need for Mechanical ventilation

1077

Figure 5D Sensitivity Analysis excluding Galan et al : Need for Mechanical ventilation

1079

1080   **Figure 5E Adverse events**

Study or Subgroup	Ivermectin Events	Total	No Ivermectin Events	Total	Weight	Odds Ratio M-H, Random, 95% CI
Afsar et al	0	41	0	54		Not estimable
Ahmed et al	0	45	0	23		Not estimable
Babalola et al	0	42	0	20		Not estimable
Biber et al	2	47	1	42	1.1%	1.82 [0.16, 20.85]
Bukhari et al	0	41	0	45		Not estimable
Camprubi et al	3	13	4	13	2.1%	0.68 [0.12, 3.87]
Chaccour et al	5	12	5	12	2.5%	1.00 [0.20, 5.07]
Chowdhury et al	19	60	26	56	11.3%	0.53 [0.25, 1.14]
Espitia-Hernandez et al	3	28	0	7	0.7%	2.06 [0.10, 44.48]
Galan et al	8	53	16	115	7.7%	1.10 [0.44, 2.76]
Gorial et al	0	16	0	71		Not estimable
Huvemec group	0	50	0	50		Not estimable
Kroleweicki et al	13	30	5	15	3.9%	1.53 [0.42, 5.58]
Lopez-Medina et al	156	200	163	198	25.7%	0.76 [0.46, 1.25]
Mahmud et al	9	185	0	180	0.8%	19.43 [1.12, 336.37]
Mohan et al	14	100	6	52	6.2%	1.25 [0.45, 3.47]
Mourya et al	0	50	0	50		Not estimable
Okumus et al	0	30	3	30	0.7%	0.13 [0.01, 2.61]
Pott-Junior et al	7	27	2	4	1.4%	0.35 [0.04, 2.98]
Shahbaznejad et al	0	35	0	34		Not estimable
Vallejos et al	45	250	53	251	31.8%	0.82 [0.53, 1.28]
Veerapaneni et al	8	50	4	50	4.0%	2.19 [0.61, 7.81]
Total (95% CI)		**1405**		**1372**	**100.0%**	**0.87 [0.67, 1.13]**
Total events	292		288			

Heterogeneity: Tau² = 0.00; Chi² = 13.14, df = 13 (P = 0.44); I² = 1%
Test for overall effect: Z = 1.05 (P = 0.30)

1081
1082

1083 **Figure 5F Sensitivity Analysis excluding Veerapaneni et al : Adverse events**

1084

1085 **Figure 6: Meta-analysis for Ivermectin use and need for Viral Clearance, Time to achieve**
1086 **viral clearance, Need for hospitalization and Duration of hospital stay**

1087 **Figure 6A Viral Clearance**

1088

1089   **Figure 6B Time to achieve viral clearance**

1090
1091   **Figure 6C Need for hospitalization**

1092

1093   **Figure 6D Duration of hospital stay**

Study or Subgroup	Ivermectin Mean	SD	Total	No Ivermectin Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% CI
Abd-elsalam et al	8.82	4.94	82	10.97	5.28	82	11.1%	-2.15 [-3.72, -0.58]	
Ahmed et al (IVM)	9.6	4.5	22	9.7	3.35	23	10.2%	-0.10 [-2.43, 2.23]	
Gonzalez et al (IVM vs placebo)	7	5.4	36	5.33	2.3	37	10.7%	1.67 [-0.24, 3.58]	
Gorial et al	7.62	2.75	16	13.22	5.9	71	10.7%	-5.60 [-7.52, -3.68]	
Khan et al	8.66	2.25	115	15.33	5.24	133	11.6%	-6.67 [-7.65, -5.69]	
Niaee et al	6.93	2.74	120	8.53	3.92	60	11.5%	-1.60 [-2.71, -0.49]	
Rajter et al	8.1	6.95	173	7	4.5	107	11.3%	1.10 [-0.24, 2.44]	
Shahbaznejad et al	6.9	3.1	35	8.3	3.3	34	11.2%	-1.40 [-2.91, 0.11]	
Veerapaneni et al	6.67	2.01	50	7.89	2.35	50	11.7%	-1.22 [-2.08, -0.36]	
Total (95% CI)			649			597	100.0%	-1.80 [-3.69, 0.08]	

Heterogeneity: Tau² = 7.67; Chi² = 141.10, df = 8 (P < 0.00001); I² = 94%
Test for overall effect: Z = 1.88 (P = 0.06)

1094